Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy-Reference-Cited by-同舟云学术

Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy

Published:2021-12-14 Issue:2 Volume:23 Page:263-272
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Marchetti Monia¹,Albertin Luca¹,Limberti Giulia¹,Canicattì Manuela²

Affiliation:

1. Hematology Unit & Transplant Center, Azienza Ospedaliera Ss Antonio E Biagio E Cesare Arrigo, Alessandria, Italy

2. Oncology Unit, Hospital Cardial Massaia, ASLAT, Asti, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2021.2014453

Reference66 articles.

1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: leukemia – acute myeloid leukemia (AML). 2016. Available at: https://seer.cancer.gov/statfacts/html/amyl.html. Accessed 2020 Mar 22

2. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States

4. Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey

5. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia;Leukemia & Lymphoma;2024-04-22

2. An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT;International Journal of Molecular Sciences;2021-12-16